Psyence Biomedical Shares Fall Over 12% After Monday Surge
Psyence Biomedical Ltd shares traded lower by more than 12% on Tuesday, following a 72.63% increase on Monday. The decline appears linked to investors selling shares after the recent gain. The prior rally occurred amid reports of a U.S. executive order accelerating reviews for psychedelic drugs.
dawn.comPsyence Biomedical Ltd (NASDAQ: PBM) shares declined more than 12% during trading on Tuesday, reversing gains from the previous day. The stock had risen 72.63% in regular trading hours on Monday. This surge coincided with developments in the psychedelic sector.
A U.S. executive order was signed to accelerate treatments for mental illness, including faster reviews for psychedelic drugs. The order also includes a reported $50 million commitment for ibogaine research. Investors appeared to engage in profit-taking following the stock's rapid increase. The company focuses on biomedical applications in the psychedelic field.
The psychedelic sector received attention due to the executive action targeting mental health treatments. No further details on the order's implementation were provided in the report. Psyence Biomedical's stock movement reflects broader interest in psychedelic-based therapies. Trading volume and future developments may influence the share price in coming sessions.
Key Facts
Story Timeline
3 events- Tuesday, 2026-04-21
Psyence Biomedical shares traded lower by more than 12% amid apparent profit-taking.
1 sourceBenzinga - Monday, 2026-04-20
The stock rose 72.63% following reports of a U.S. executive order on psychedelic drugs.
1 sourceBenzinga - Recent
A U.S. executive order was signed to accelerate mental illness treatments including psychedelics.
1 sourceBenzinga
Potential Impact
- 01
Psyence Biomedical may see increased trading volatility in the psychedelic sector.
- 02
The executive order might lead to faster drug approvals in mental health.
- 03
Other psychedelic companies could experience similar stock movements.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.